New pill for chronic hives tested in everyday clinics
NCT ID NCT07642557
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study follows 470 adults with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will track how well it controls symptoms and any side effects over two years in real-world clinics. The goal is to see if remibrutinib works as well outside of strict trial settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Remibrutinib
- What this could lead to
- If successful, this could show that remibrutinib effectively controls chronic hives in everyday practice, offering a new treatment option for patients.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. It is also early in real-world testing, and effectiveness may vary across patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGDüren, 52349, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.